Efficacy and Safety of Durvalumab Combined with Daratumumab in Daratumumab-Refractory Multiple Myeloma Patients

SIMPLE SUMMARY: The CD38-targeting antibody daratumumab has marked activity in multiple myeloma through direct anti-tumor effects and immunomodulatory activity. However, eventually most patients will develop daratumumab-refractory disease. We hypothesized that daratumumab-resistance could be reverse...

Full description

Saved in:
Bibliographic Details
Published in:Cancers (Basel)
Main Authors: Frerichs, Kristine A., Verkleij, Christie P. M., Dimopoulos, Meletios A., Marin Soto, Jhon A., Zweegman, Sonja, Young, Mary H., Newhall, Kathryn J., Mutis, Tuna, van de Donk, Niels W. C. J.
Format: Artigo
Language:Inglês
Published: MDPI 2021
Subjects:
Article
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC8158123/
https://ncbi.nlm.nih.gov/pubmed/34070044
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers13102452
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items